Total Payments
$297,913
2024 Payments
$48,631
Companies
29
Transactions
267
Medicare Patients
918
Medicare Billing
$150,689
Payment Breakdown by Category
Consulting$231,807 (77.8%)
Travel$23,358 (7.8%)
Other$20,818 (7.0%)
Food & Beverage$12,213 (4.1%)
Research$9,616 (3.2%)
Education$101.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $231,807 | 90 | 77.8% |
| Travel and Lodging | $23,358 | 49 | 7.8% |
| Honoraria | $12,256 | 4 | 4.1% |
| Food and Beverage | $12,213 | 114 | 4.1% |
| Unspecified | $9,616 | 6 | 3.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,562 | 2 | 2.9% |
| Education | $101.00 | 2 | 0.0% |
Payments by Type
General
$288,297
261 transactions
Research
$9,616
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $75,031 | 68 | $0 (2024) |
| Daiichi Sankyo Inc. | $43,361 | 37 | $0 (2024) |
| AstraZeneca UK Limited | $21,960 | 8 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $19,633 | 11 | $0 (2024) |
| Eli Lilly and Company | $18,595 | 16 | $0 (2024) |
| Merck Sharp & Dohme LLC | $14,505 | 14 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $13,662 | 3 | $0 (2023) |
| Gilead Sciences, Inc. | $11,547 | 12 | $0 (2024) |
| Amgen Inc. | $10,559 | 9 | $0 (2024) |
| ABBVIE INC. | $10,240 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,631 | 42 | AstraZeneca Pharmaceuticals LP ($15,481) |
| 2023 | $50,429 | 54 | AstraZeneca Pharmaceuticals LP ($11,387) |
| 2022 | $35,988 | 28 | Daiichi Sankyo Inc. ($23,025) |
| 2021 | $46,158 | 16 | AstraZeneca Pharmaceuticals LP ($18,860) |
| 2020 | $31,860 | 26 | AstraZeneca Pharmaceuticals LP ($6,938) |
| 2019 | $39,643 | 37 | AstraZeneca UK Limited ($11,000) |
| 2018 | $21,511 | 31 | AstraZeneca Pharmaceuticals LP ($8,116) |
| 2017 | $23,693 | 33 | AstraZeneca Pharmaceuticals LP ($6,033) |
All Payment Transactions
267 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Amgen Inc. | IMDELLTRA (AMG 757) (Biological) | Consulting Fee | Cash or cash equivalent | $686.00 | General |
| Category: Hematology | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| 11/04/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| 11/04/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 10/29/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| 10/21/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,592.50 | General |
| 10/11/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| 10/01/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,744.00 | General |
| 09/25/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $485.00 | General |
| 09/16/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| 09/13/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $76.14 | General |
| 09/11/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| 09/07/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $71.44 | General |
| 09/07/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 09/07/2024 | Amgen Inc. | IMDELLTRA (AMG757) (Biological) | — | In-kind items and services | $24.15 | Research |
| Study: Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial • Category: Hematology | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $46.71 | General |
| Category: ONC | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $43.58 | General |
| Category: ONC | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $25.48 | General |
| Category: ONC | ||||||
| 08/09/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $686.00 | General |
| 08/06/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $3,082.50 | General |
| Category: Oncology | ||||||
| 07/11/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $3,767.50 | General |
| 06/25/2024 | Fosun Pharma USA Inc. | Serplulimab (Biological) | Honoraria | Cash or cash equivalent | $3,000.00 | General |
| Category: Oncology | ||||||
| 06/25/2024 | Fosun Pharma USA Inc. | Serplulimab (Biological) | Food and Beverage | In-kind items and services | $220.09 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 1B STUDY OF LY3295668 ERBUMINE MONOTHERAPY IN PATIENTS WITH PLATINUM-SENSITIVE, EXTENSIVE-STAGE SMALL-CELL LUNG CANCER | Eli Lilly and Company | $5,895 | 2 |
| LIBRETTO-432: A PLACEBO-CONTROLLED DOUBLE-BLINDED RANDOMIZED PHASE 3 STUDY OF ADJUVANT SELPERCATINIB FOLLOWING DEFINITIVE LOCOREGIONAL TREATMENT IN PARTICIPANTS WITH STAGE IB-IIIA RET FUSION-POSITIVE NSCLC | Eli Lilly and Company | $3,582 | 2 |
| Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage Small Cell Lung Cancer: DeLLphi-305 Phase 3 Trial | Amgen Inc. | $24.15 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 226 | 355 | $198,178 | $36,548 |
| 2022 | 7 | 246 | 395 | $229,697 | $42,570 |
| 2021 | 6 | 211 | 355 | $166,872 | $37,540 |
| 2020 | 7 | 235 | 431 | $145,325 | $34,030 |
Total Patients
918
Total Services
1,536
Medicare Billing
$150,689
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 33 | 62 | $44,956 | $7,340 | 16.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 48 | $34,992 | $5,883 | 16.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 36 | 59 | $24,052 | $4,883 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 37 | 62 | $25,236 | $4,805 | 19.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 45 | $17,955 | $4,571 | 25.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 26 | 26 | $22,699 | $4,021 | 17.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $11,429 | $2,011 | 17.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $9,298 | $1,479 | 15.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 16 | $4,470 | $789.46 | 17.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 11 | $3,091 | $765.82 | 24.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 45 | 92 | $65,545 | $11,030 | 16.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 28 | 59 | $42,082 | $7,252 | 17.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 35 | 35 | $30,277 | $5,194 | 17.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 58 | $23,142 | $5,065 | 21.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 37 | 58 | $23,206 | $4,646 | 20.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 23 | 37 | $14,791 | $3,139 | 21.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $10,514 | $2,304 | 21.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $9,541 | $1,736 | 18.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 13 | 16 | $6,384 | $1,272 | 19.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 15 | 15 | $4,215 | $931.98 | 22.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 42 | 96 | $57,038 | $12,113 | 21.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 44 | 73 | $24,727 | $6,331 | 25.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 32 | 32 | $23,810 | $5,041 | 21.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 52 | $20,748 | $4,662 | 22.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 17 | 35 | $20,909 | $4,463 | 21.3% |
About Dr. Jacob Sands, MD
Dr. Jacob Sands, MD is a Internal Medicine healthcare provider based in Burlington, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2007. The National Provider Identifier (NPI) number assigned to this provider is 1356491237.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jacob Sands, MD has received a total of $297,913 in payments from pharmaceutical and medical device companies, with $48,631 received in 2024. These payments were reported across 267 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($231,807).
As a Medicare-enrolled provider, Sands has provided services to 918 Medicare beneficiaries, totaling 1,536 services with total Medicare billing of $150,689. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Burlington, MA
- Active Since 01/11/2007
- Last Updated 12/18/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1356491237
Products in Payments
- TAGRISSO (Drug) $24,172
- IMFINZI (Biological) $20,965
- ZEPZELCA (Drug) $19,539
- IMFINZI (Drug) $11,510
- Trodelvy (Drug) $8,497
- GILOTRIF (Drug) $6,952
- ALUNBRIG (Drug) $5,445
- superDimension (Device) $5,092
- FOUNDATIONACT (Device) $4,379
- LORBRENA (Drug) $3,616
- Serplulimab (Biological) $3,220
- COSELA (Drug) $3,007
- TECENTRIQ (Biological) $2,840
- SuperDimension (Device) $2,491
- Abraxane (Drug) $1,800
- Vitrakvi (Drug) $1,624
- IMDELLTRA (AMG 757) (Biological) $686.00
- Udenyca (Biological) $488.07
- ZEJULA (Drug) $386.68
- FOUNDATIONONE CDX (Device) $364.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Burlington
Benjamin Littenberg, Md, MD
Internal Medicine — Payments: $234,650
Internal Medicine $234,650
Dr. Jonathan Silver, M.d, M.D
Internal Medicine — Payments: $81,151
Internal Medicine $81,151
Fuad Aleskerov, M.d, M.D
Internal Medicine — Payments: $69,505
Internal Medicine $69,505
Dr. David Cleary, M.d, M.D
Internal Medicine — Payments: $63,836
Internal Medicine $63,836
Dr. Anna Solum, Md, MD
Internal Medicine — Payments: $53,644
Internal Medicine $53,644
David Martin, M.d, M.D
Internal Medicine — Payments: $45,703
Internal Medicine $45,703